Regulus Therapeutics Inc.
RGLS
$2.06
$0.126.19%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 58.25% | 140.41% | 76.54% | 61.99% | 66.90% |
| Gross Profit | -58.25% | -140.41% | -76.54% | -61.99% | -66.90% |
| SG&A Expenses | 47.37% | 36.29% | 28.70% | 9.76% | 1.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.86% | 49.95% | 28.55% | 12.15% | 10.16% |
| Operating Income | -60.86% | -49.95% | -28.55% | -12.15% | -10.16% |
| Income Before Tax | -54.34% | -44.69% | -24.19% | -9.13% | -6.05% |
| Income Tax Expenses | 0.00% | 0.00% | 0.00% | -- | 0.00% |
| Earnings from Continuing Operations | -54.34% | -44.69% | -24.18% | -9.13% | -6.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.34% | -44.69% | -24.18% | -9.13% | -6.05% |
| EBIT | -60.86% | -49.95% | -28.55% | -12.15% | -10.16% |
| EBITDA | -60.92% | -49.74% | -28.22% | -11.80% | -9.83% |
| EPS Basic | 44.85% | 32.25% | 25.65% | 20.21% | 14.84% |
| Normalized Basic EPS | 44.85% | 32.26% | 25.66% | 20.22% | 14.84% |
| EPS Diluted | 44.85% | 32.41% | 25.81% | 20.37% | 15.01% |
| Normalized Diluted EPS | 44.85% | 32.26% | 25.66% | 20.22% | 14.84% |
| Average Basic Shares Outstanding | 195.77% | 147.06% | 96.39% | 38.62% | 24.22% |
| Average Diluted Shares Outstanding | 195.77% | 147.06% | 96.39% | 38.62% | 24.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |